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ABSTRACT
AN EXAMINATION OF AFFECTIVE BLUNTING IN RODENTS
By
Sigrid R. Crowel
Major Depressive Disorder (MDD) is the leading cause of disability worldwide.
The prevalence of MDD is 12% in men and 20% in women. Antidepressant drugs are the
first line of treatment in Major Depressive Disorder and other mood disorders,
particularly selective-serotonin reuptake inhibitors. Affective blunting is a potential side
effect of chronic SSRI treatment, which can be defined as a diminished response to
pleasurable or unpleasant stimuli, and is indicated as a marked indifference towards
engagement in activities. The present study looked to examine the effects of chornic
fluoxetine (0.16g/L) administration on pre-test and post-test performance of a light
aversion task and a sucrose preference test. The light aversion task presents subjects with
a bright aversive light which can be terminated by a head-entry into an apparatus, and are
measured as escape responses. The sucrose preference test measures amount of sucrose
consumption pre and post treatment. A significance was found in the male fluoxetine
group, who performed significantly less escape responses than before treatment. There
were no significant differences between treatment groups found in female operant
responding, nor in the sucrose preference test. This study is the first known attempt to
exhibit affective blunting in an animal model.
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Literature Review

Major Depressive Disorder (MDD) is characterized by five or more of the
following symptoms: depressed mood, noticeable diminished interest in activities once
found enjoyable, significant bodyweight changes (5% of body weight within one month),
insomnia or hypersomnia, psychomotor agitation, daily fatigue, excessive ill-suited guilt,
diminished ability of concentration, and/or reoccurring thoughts of death. These
symptoms of depression must cause clinically impaired functioning in social or
occupational areas of life (American Psychiatric Association, 2013). Clinically,
depression can have multiple dimensions, and the DSM-5 classifies these as specifiers.
For example, an individual with major depressive disorder with “anxious distress”
indicates that the individual experiences anxiety-related symptoms as well (American
Psychiatric Association, 2013).
Major depressive disorder is ranked as the leading cause of disability worldwide
by the World Health Organization (2018). According to the Centers for Disease Control
and Prevention, nearly 3% of Americans aged 12 and older have had severe depressive
symptoms, 4.7% have had moderate symptoms, and 15.3% have had mild symptoms. The
prevalence of chronic major depressive disorder in the United States is 12% in men and
20% in women (Belmaker & Agam 2008). Greenberg et al. (2015) estimated the
economic burden of depression to be $210.5 billion in 2010, which has grown from $53
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billion in 2003 (Wang, Simon, & Kessler, 2003). The suicide rate in depressed patients is
10-15%, and 60-70% of patients with depression have suicidal ideation (Möller 2003).
Treatments for depression can include psychotherapeutic interventions and
pharmacological treatments. Cognitive behavioral therapy is the most widely used
psychotherapeutic approach to treating mental disorders (Forman, Herbert, Moitra,
Yeomans, & Geller, 2007). While cognitive behavioral therapy is the most commonly
studied for psychotherapy, this may have led to over estimation of its effectiveness
(Cuijpers, Berking, Anderson, Quigley Kleiboer, & Dobson, 2013). Antidepressant drug
use has increased from 6.8% of the population (1999-2000) to 13% of the population
(2011-2012). Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) and Selective
Serotonin Reuptake Inhibitor (SSRI) treatments have been key in facilitating the growth
of antidepressant drug use. SNRI use increased from 0.4% (1999-2000) to 2.0% (20112012), and SSRI use increased from 4.3% (1999-2000) to 8.5% (2011-2012) (Kantor,
Rehm, Haas, Chan, & Giovannucci, 2015). Möller (2003) conducted a meta-analysis that
reported the most common and effective treatment for major depressive disorder, as well
as depressed mood and anxiety disorders, is antidepressant drug therapy.
Neurobiology of depression
The neuropathology of depression is complex and studies have found both
structural changes and differences in structural activity in patients with major depressive
disorder. Drevets et al. (1997) conducted a study that used positron emission tomography
to assess cerebral blood flow and glucose metabolism to measure brain activity in
depressed patients. They found decreased activity in the subgenual area of the prefrontal
cortex. Coinciding with these findings, a study using magnetic resonance imaging (MRI)
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found the volume of this structure reduced in patients with major depressive disorder
(Drevets et al., 1997).
The nucleus accumbens also appears to be affected among patients with
depression. The nucleus accumbens regulates reward and motivation, an aspect that is
often referred to as an inability to respond to hedonic stimuli (Berlin et al., 1998).
Schlaepfer et al. (2008) conducted a study using deep brain stimulation in the nucleus
accumbens for treatment-resistant depression in three individuals. The researchers found
that after only 60-s of stimulation of the nucleus accumbens, patients exhibited an
immediate interest in doing novel activities or engaging in activities they once enjoyed
doing.
Increased resting blood flow in the amygdala, a structure important for fear and
aggression, appears in depressed individuals (Drevets et al., 1992; Gotlib & Joormann,
2010). Drevets et al. (1992) conducted a PET assessment showing decreased activity in
the left amygdala. Later studies by the same research group concluded that glucose
uptake is also increased in the left amygdala in those with depression, implying greater
activity in this area (Drevets, Bogers, & Raichle, 2002).
Becker et al. (2007) has proposed that a vital function of the hippocampus is to
apply negative-feedback control over the hypothalamic-pituitary-adrenal axis, which is
responsible for the body’s stress response. Another function the hippocampus is to exert
negative-feedback to the amygdala, nucleus accumbens, and medial prefrontal cortex,
which are structures responsible for motivation and emotion processing. Malberg, Eisch,
Nestler, and Duman (2000) examined the effects of antidepressant drug treatment on
hippocampal neurogenesis in the adult male rat. Their study tested three different
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antidepressant drugs (fluoxetine [SSRI], reboxetine [norepinephrine reuptake inhibitor],
and tranylcypromine [monoamine oxidase inhibitor, MAOI]) against saline, as well as a
negative control (haloperidol [typical antipsychotic drug]). Negative controls in
psychopharmacology are treatments in which either no response or response in the
opposite direction of the experimental hypothesis is expected. Results from this
experiment showed that antidepressant drug treatment caused increased proliferation of
cells in the dentate gyrus of the hippocampus, whereas haloperidol did not show an
increase in proliferation. Whether or not these new cells mature at an accelerated rate was
inconclusive, however, evidence suggests that fluoxetine does increase the maturation of
these new cells.
Wang, David, Monckton, Battaglia, and Hen (2008) studied whether or not
chronic fluoxetine administration to rats would have an influence on maturation of new
hippocampal granule cells. The authors found that chronic fluoxetine administration
resulted in doublecortin-positive immature neurons displaying an increase in dendritic
branching. Coinciding with this finding, there was a significant increase of mature neuron
markers found after chronic fluoxetine administration. These findings suggest that
antidepressants not only promote neurogenesis, but also increase the likelihood of those
cells maturing. The importance of antidepressant drugs having an influence on
hippocampal cell maturation is due to the hippocampus’ role in emotional memory. The
hippocampus has abilities to associate episodic memory with aversive or positive
emotions by communication with the amygdala, which is responsible for informing us if
a situation is dangerous or pleasant.
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Much of the support for the neurochemistry in the neuropathology of depression
comes from pharmacological effects of antidepressant drugs (see below). One of the
earliest theories of depression is the Monoamine-Deficiency Hypothesis. This hypothesis
suggests depression is due to diminished levels of monoamine neurotransmitters, given
that antidepressant drugs increase monoamine neurotransmitter levels.
Antidepressant Drugs
The discovery of antidepressant drug therapy occurred by accident. In the 1950’s,
the drug iproniazid was developed for the purpose of treating tuberculosis. In 1952,
studies were taking place to assess the clinical effects of iproniazid, specifically at the
Sea View Hospital of Staten Island. Patients undergoing this treatment showed an allaround increased feeling in energy, as well as greater interest in being social. Clinicians
reported that despite the physical ailments associated with tuberculosis, patients were
actually dancing in the hallways with one and other. The energy that patients were
experiencing was so grand, that the staff believed the patients were well enough to leave
the hospital. Despite the attempts to brand iproniazid as a psychiatric treatment, it would
only ever be marketed as a tuberculosis treatment (López-Muñoz & Alamo 2009).
The accidental findings of iproniazid’s antidepressant effects led to the first class
of antidepressant treatment, known as MAOIs. MAOIs bind to monoamine oxidase
(MAO) enzymes in the body, preventing the breakdown of monoamine neurotransmitters
(i.e., dopamine, norepinephrine, and serotonin.). It was unknown that MAOIs would
elevate levels of tyramine, which would otherwise be metabolized by MAO. Tyramine is
often produced by foods that are primarily aged or fermented (this includes cheese and
alcohol). The effect of tyramine during MAOI treatment can cause increased blood
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pressure that is so high, it could be lethal. This interaction is commonly known as the
Cheese Effect (Mc-Cabe-Sellers, Staggs, & Bogle, 2006).
Although the first MAOIs were not well tolerated by patients, they led the way
toward research and development for other antidepressant drugs. Tricyclic
antidepressants (TCAs) were the next antidepressants introduced after MAOIs, which
was discovered in 1955, as an experimental antidepressant compound (Brown &
Rodolsky, 2015). TCAs block the reuptake of norepinephrine and serotonin (Lennox &
Frazer, 2002). These treatments tended to also not be tolerated well by patients due
largely to anticholinergic side effects, such as dry mouth, constipation, blurred vision,
confusion, and delirium. One of the most common side effect of TCAs is sedation, due to
the anticholinergic and antihistaminergic effects (Zajecka & Tummala, 2002). It is also
worth noting that TCAs slow cardiac conduction, and their cardiotoxicity is so high that a
fatal overdose can occur with 1 week worth of medication (Khawam, Laurencic, &
Malone 2006).
The newer classes of antidepressant drugs are SSRIs, SNRIs, and norepinephrinedopamine reuptake inhibitors (NDRIs, e.g., bupropion). SSRIs act upon inhibiting the
reuptake of serotonin, while SNRIs inhibit the reuptake of serotonin and norepinephrine.
Blocking reuptake of these neurotransmitters means there will be an increased amount of
serotonin and/or norepinephrine in the synaptic cleft. NDRIs inhibit the reuptake of
norepinephrine and dopamine (Ascher et al., 1995).
Antidepressant drug therapy is the leading treatment for depressed mood, major
depressive disorder, and anxiety disorders. SSRIs are the most common types of
antidepressant drugs prescribed, due to their tolerability by patients (Opbroek et al.,
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2002). However, the delay in the onset of antidepressant effects can last from two to six
weeks. They also have side effects specifically linked to inhibition of serotonin reuptake.
Weight gain and sexual dysfunction are some of the more common side effects a patient
might experience when beginning treatment with an antidepressant that elevates serotonin
levels (Demyttenaere & Jaspers 2008). These effects usually subside within a few weeks
of continuing treatment, however conjunctive therapy is an increasingly more common
area to treat these effects. Commonly used conjunctive therapy includes the addition of
the NDRI bupropion. A more severe side effect that may take place, especially with a
sudden increase in dose, is the serotonin syndrome (Birmes et al., 2003). The serotonin
syndrome consists of physical ailments such as increased body temperature and tremor,
which could result in death if treatment continued, and mental ailments such as agitation
(Boyer & Shannon, 2005).
Abruptly ceasing SSRI treatment can lead to the serotonin discontinuation
syndrome. Certain symptoms associated with discontinuation syndrome are not specific
to SSRI discontinuation, but can also present following discontinued use of any
antidepressant drug that includes significant inhibition of serotonin reuptake as a
mechanism of action, such as tricyclic antidepressant drugs or SNRIs. These symptoms
include nausea, headache, insomnia, akathisia (movement disorder), behavior resembling
mania, dizziness, and vertigo (Schatzberg et al., 1997). Another symptom of serotonin
discontinuation syndrome comes in the form of sensory abnormalities. Specifically,
patients have described the feeling of an electric “shock-like” sensation or a “jolt.” This
feeling occurs in up to 5% of SSRI patients who abruptly discontinue use (Frost et al.,
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1995). The serotonin discontinuation syndrome can be prevented by tapering off the
doses of the medication (Black et al, 2000).
Affective Blunting
While SSRIs are effective for attenuating depressive and anxious symptoms, use
of these treatments could result in a side effect known as affective blunting. Affective
blunting can be defined as a diminished response to pleasurable or unpleasant
stimuli. Hoen-Saric et al. (1990) gathered case studies of patients treated with SSRIs
who reported a lack of engagement in activities that they were once interested in.
Indifference toward engagement ranged from not caring about paying utility bills to
losing interest in their professional work.
While these observations were noted in patients treated with SSRIs, some
elements appear similar to symptoms found in depression. The DSM-5 reports one
symptom of depression being diminished interest and/or pleasure in almost all activities,
which contributes to the difficulty in establishing a definition for affective blunting.
While this is a defined symptom in the DSM-5 (American Psychiatric Association, 2013),
individuals diagnosed with depression also exhibit extreme emotional responding. For
example, those diagnosed with depression often exhibit greater irritability that presents as
an exaggerated frustration response over seemingly minor incidents (American
Psychiatric Association, 2013).
The DSM-5 focuses on the reduction of engagement in pleasurable activities, yet
does not include diminished responding to aversive situations. The inability to be
substantially affected by negative situations seems to be due to prolonged SSRI
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treatment. For instance, patients report an inability to cry in situations where this
response would be appropriate (Price et al., 2009; Opbroek et al., 2002).
Opbroek et al., (2002) conducted a study to quantify emotional blunting
symptoms in individuals diagnosed with depression who were being treated with SSRI
antidepressant drugs. Five subjects each were treated with either fluoxetine, paroxetine,
or sertraline. All of the individuals diagnosed with depression were determined to be in
remission following the criteria of the Hamilton Depression Rating Scale (HAMD), to
ensure that their feelings could not be attributed to depression. A control group was
composed of hospital employees where the participants were chosen from, these
employees had never been diagnosed with Major Depressive Disorder. The authors of
this study designed a psychometric measurement named the Laukes Emotional Intensity
Scale (LEIS) (Opbroek et al., 2002). This assessment consists of 18 emotional states: (1)
ability to cry, (2) feel motivated, (3) feel irritated or upset, (4) interest in sex, (5) care
about others feelings, (6) feel sadness, (7) have erotic dreams, (8) enjoy eating, (9) feel
energetic, (10) have creativity, (11) feel surprise, (12) become angry, (13) expression of
feelings, (14) pleasure during sex, (15) feel joy, (16) involved and interest in work, (17)
experience worry, and (18) feel assertive.
The results of this study showed that individuals undergoing SSRI treatment
showed emotional blunting in the following items: 1-7, 10-14, and 17. Total mean scores
for LEIS in the treatment group of participants were shown to be statistically lower than
for controls. One limitation that Opbroek et al. (2002) found is that those individuals
chosen for this treatment group had previously been involved in a study measuring the
relationship between SSRI treatment and sexual dysfunction. Also, the number of
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subjects in this study were small (N=15). Regardless of these limitations, this empirical
evidence gives a direction for further research in larger studies. It would be helpful to
also include other antidepressant drug treatments, such as SNRIs and NDRIs
Price, Cole, and Goodwin (2009) conducted a qualitative study of individual,
group and validation interviews, to better understand emotional blunting in individuals on
SSRI treatment. The blunting of emotions was broken down into eight categories in this
experiment: “general emotional affect,” “reduction of positive emotions,” “reduction of
negative emotions,” “emotional detachment,” “just not caring,” “changed personality,”
and “effects on everyday life.” Almost all patients conveyed emotions as being
‘flattened’ or ‘numbed,’ for some patients even completely ‘blocked.’ Most individuals
reported a reduction in both positive and negative emotions. While reduction in
emotional distress is often seen as beneficial for depression, lacking enjoyment of social
situations or loved hobbies is a potential limitation to treatment. Many participants
attributed reduced motivation to their SSRI medication. These authors concluded that all
emotional effects were attributed to, in whole or in part, the patient’s antidepressant
medication.
One theory of depression is the emotional-context insensitivity hypothesis, which
proposes that depressed individuals have a weakened response to positive and negative
environmental stimuli, which can be characterized as blunted affect (Carlson et al., 2017).
Grillon et al., (2013) claim, however, that major depressive disorder (MDD) is not
supported by the emotional-context insensitivity hypothesis. The authors conducted a
startle reflex experiment where the MDD group showed high levels of startle while
anticipating shock, when compared with a control group. Therefore, the participants with
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MDD were capable of exhibiting a strong negative response. Patients have noted their
lack of drive was unlike that of sedation or previous depressive episodes (Hoen-Saric et
al., 1990; Opbroek et al., 2002).
Despite affective blunting’s uniqueness, there appears to be a need to examine
this effect closer, and displays a need for representation in animals. Due to the limited
research in affective blunting as a potential side effect of antidepressant drug use it needs
to be thoroughly examined in animal models before they move on to clinical trials.
Animal models for screening antidepressant drugs
The forced swim test (behavioral despair model) and tail suspension test are two
animal models of depression used for screening antidepressant drug efficacy. Forced
swim test is conducted by placing a rat or mouse in a beaker of water, and then measuring
time of immobility and latency of immobility. Antidepressant drugs decrease immobility
and latency of immobility in this model. Tail suspension infers a similar interpretation as
forced swim, in the form of mobility, except mice are suspended by their tail for several
minutes. Petit-Demouliere et al. (2005) conducted a study comparing an SSRI and SNRI
using the tail suspension paradigm. The authors found that both fluoxetine and
venlafaxine reduced the amount of immobility in mice, but fluoxetine produces less of an
effect than venlafaxine.
Another model for depression in animals is learned helplessness. A learned
helplessness task will typically involve a group of animals presented with inescapable
shock since the start of training, against another group given escapable shock since the
start of training. Motivation can be observed when being presented with inescapable trials
of shock. For example, Hannum et al. (1989) conducted a study with rats presented with
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inescapable shock since being weaned, against a group of rats presented with no shock or
escapable shock. The authors found that when all rats were later presented with
conditions of escapable shock, rats with inescapable shock since being weaned failed to
escape the shock even if it were escapable. Failing to escape a shock can be described as
failure to move throughout the shuttle box to an area without shock or failing to press a
lever that terminates the shock. Seligman & Groves (1970) conducted a study that
revealed emotional deficits present with inescapable shock. After one session of
inescapable shock, rats failed to escape escapable shock after 5 minutes, 1 hour, 24 hours,
and 168 hours. Takamori et al. (2002) did a similar study testing three different
antidepressants; imipramine (tricyclic), tranylcypromine (monoamine-oxidase inhibitor),
and fluvoxamine (selective serotonin reuptake inhibitor) and dopamine receptor agonists;
SKF38393 (D receptor agonist), quinpirole (D receptor agonist), and 7-OH-DPAT (D
1

2

3

receptor agonist), using the learned helplessness paradigm. Measuring escape failures
consists of the times the subject does not move to the part of the shuttle box where shock
is not being applied to the grid floor. All three antidepressants tested reduced number of
escape failures, and so did the D and D receptor agonists, but not the D receptor agonist.
1

2

3

It is possible to study levels of motivation in laboratory animals. A common
representation of anhedonia, or the inability to engage in pleasurable activities, is the
sucrose preference test. The sucrose preference test presents subjects with a choice
between sucrose solution or tap water. It is expected that an animal will drink from the
sucrose water as opposed to tap water, the reason being is that sucrose has added reward
compared to plain tap water (Rygula et al., 2005). Sucrose preference can be reduced by
chronic mild stress (CMS), which involves alteration to housing conditions (e.g. tilted
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cage, soiled bedding, new house mates). Willner et al. (1987) concluded that tricyclic
antidepressant treatment could reverse the effects that chronic mild stress had on sucrose
preference. Muscrat, Papp, and Willner (1992) found that the tricyclic antidepressant
maprotiline and the SSRI fluoxetine could reverse the effects of chronic mild stress
induced lack of sucrose preference. Sucrose, employed as a rewarding stimulus, can be
measured by consumption before and after chronic antidepressant treatment to see if
preference has changed. Lack of engagement will be displayed as a lack of preference
between sucrose water and tap water.
Animal models for screening side effects of SSRIs
While many animal models of depression are available, there are few animal
behavioral models for examining antidepressant side effects. A study conducted by
Cantor, Binik and Pfaus (1998) evaluated the sexual behavior of male rats chronically
treated with fluoxetine and their interaction with receptive females. The greatest deficits
appeared as decreased appetitive sexual behavior and decreased ejaculation frequency.
Another study, this time using female rats, was done to measure how fluoxetine disrupts
the estrous cycle (Uphouse, Hensler, Sarkar, and Grossie, 2006). These authors
concluded that the estrous cycle was lengthened and progesterone blood levels were
decreased with fluoxetine treatment. However, continuing administration of fluoxetine
past 17 days did appear to regulate sexual behavior in these female rats. Both studies also
reported reduced body weight in rats treated with fluoxetine. Uphouse et al. (2006) even
added a pair-fed aspect to their study, conveying that appetitive disruption on fluoxetine
treatment can contribute to sexual dysfunction.
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Effect of female estrous cycle on learning and memory
Behavioral studies of rats tend to use males due to their amount of reliability in
behavioral operant procedures. One of the reasons males are often utilized over females is
due to the variability in learning and memory at different phases of the female estrous
cycle. Female rats have an estrous cycle that last approximately 3-5 days on average.
During this time the female rat will go through four phases: proestrus, estrus, metestrus,
and diestrus (Miland et al., 2009; Warren & Juraska, 1997). Throughout the estrous cycle,
female rats will have morphological and electrophysiological changes (Warren &
Juraska, 1997) which are due to their fluctuating hormone levels. During proestrus
females will produce higher levels of estrogen and progesterone while during metestrus
and estrus phases females will produce lower levels of estrogen and progesterone (Miland
et al., 2009).
Warren & Juraska (1997) conducted a study to determine if female rat cycle
would have an effect on spatial memory in the Morris water maze (MWM). The MWM
procedure administers cues which enable the rodent to navigate the perimeter of an open
swimming arena, where they are to locate a submerged escape platform (Vorhees &
Williams, 2006). Warren & Juraska (1997) found that females during their estrus phase
(low levels of estrogen and progesterone) performed better than females during their
proestrus phase, suggesting that females perform better spatially during the estrus phase
of their cycle. Further, Miland et al. (2009) went on to measure whether or not the female
rat estrus cycle had an effect on performance in a fear conditioning task – particularly
fear extinction. The authors found that female rats in their metestrus phase (low estrogen
and progesterone) exhibited significantly greater amounts of freezing when compared to
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the group of females in their proestrus phase. The results of both of these studies suggest
that the time during a female’s estrus cycle may significantly impact their abilities to
respond during behavioral tasks.
Rationale
Depression is often viewed as a disruption in emotional processing, however,
from reviewing a multitude of studies examining the emotional side effects associated
with SSRI treatment, it appears depression and emotional side effects are not the same.
Patients have repeatedly communicated a reduction in both positive and negative
emotions, following SSRI treatment. To date, few studies have examined an association
between antidepressant treatment and affective blunting. Studies that have been
conducted were limited to surveying the prevalence and severity of affective blunting,
and there have yet to be studies aimed at exploring neuropharmacologic mechanisms
mediating these effects. Females were utilized in the present study to represent the large
amount of female human population who undergo antidepressant drug treatment.
Including them here, is representative of modeling the human population.,
The present study is a first step toward evaluating the link between SSRI
treatment and affective blunting by attempting to model these effects in laboratory rats.
We plan to observe the effects of chronic fluoxetine administration on motivation to
engage in positive stimuli and avoid aversive stimuli. Fluoxetine was chosen due to its
common prevalence when treating depressive symptoms, along with its high association
with emotionally aversive side effects. The sucrose preference test was used as a measure
of the amount of effort animals will devote to a rewarding activity and a light aversion
test was designed to measure the effort dedicated to escaping aversive conditions. It was
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hypothesized that animals treated with fluoxetine will engage less in the sucrose
preference test, consuming less sucrose than the control group. Next, it was hypothesized
that animals treated with fluoxetine will emit less escape responses after chronic
treatment. It was hypothesized that animals treated with fluoxetine will emit greater
omission responses after treatment. Hypothesis four proposed that fluoxetine treated
animals will emit less premature responses after treatment. Finally, hypothesis five
proposed that fluoxetine treated animals will have a longer latency average following
chronic administration. All tests were conducted before and after 21 days of fluoxetine
administration. The development of animal behavior models capable of displaying
affective blunting-like effects following antidepressant treatment will allow for extensive
follow up investigations into the mechanisms mediating these effects along with a
potential screening tool for affective blunting during development of novel antidepressant
drugs.
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Methods

Subjects
Thirty-eight Wistar rats (19 males and 19 females; Crl: WI strain; purchased from
Charles River Laboratories) weighing 250g-300g were used for this study. Housing and
experimental procedures took place in the Neuropsychopharmacology Laboratory at
Northern Michigan University. Animals were boarded separately in a vivarium with a
constant temperature and humidity. A 12 h light/dark cycle was programmed for the
vivarium. Experimental procedures were conducted during the dark cycle. The
procedures were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals and approved by the Institutional Animal Care and Use Committee
(IACUC) at Northern Michigan University.
Drugs
Fluoxetine was a gift from the NIMH Chemical Synthesis and Drug Supply
Program (Bethesda, MD). Fluoxetine was administered in home cage water bottles in an
amount of 0.16g/L (expressed as salt form of the drug). The water bottles were wrapped
in aluminum foil to avoid break down of the drug by light. The dose selected for this
study was based on Li et al. (2012).
Apparatus
Sucrose Preference Task.
Two water bottles, specific for rodents, were used during the sucrose preference
task. The lids attached to the water bottles were equipped with a stainless steel ball at the
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end to ensure no liquid was lost for accurate measurement of consumption. All water
bottles were covered in aluminum foil and duct tape to avoid novelty, as this is how the
fluoxetine bottles appeared.
Light Aversion Operant Task.
Operant chambers specific for rats (Med-Associates Inc., St. Albans, VT) were
used. Chambers were equipped with a aperture with a photo beam sensor, a fan for
ventilation and masking noise. The aperture was positioned 60 mm above the chamber
grid floor (Figure 1). The aperture was 40 mm in diameter and 30 mm in length. The
photobeam sensors were positioned 15 mm inside of the aperture, and a beam break was
recorded only after a continual interruption of at least 1 second. The top of the chamber
consisted of a single transparent Plexiglas panel. A 12 watt LED bulb (equivalent to 100
watt incandescent bulbs) was positioned approximately 2 cm above the chamber top,
centered over the chamber. The equipment was controlled by and data gathered by
MedPC IV for Windows (Med-Associates Inc.).

Figure 1. Represents the burrowing apparatus used for the light aversion task.
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Experimental Design
Light aversion training.
Each training session consisted of 40 trials, and the session length was 20
minutes. The experiment examined escapes by recording the frequency of head entries
and latency of head entry from the time of light activation. Escapes were defined, in this
experiment, as head entries passing the photo beams for a duration of at least 1s. A bright
light (1130 lumens) was used as an aversive stimulus during the sessions.
For escape behavior, the bright light was delivered for a duration of 30-s, unless
terminated by an escape response (head entry into response aperture). Termination of the
light by an escape response was succeeded by a 20-s period of darkness. Otherwise, the
light was terminated after the 30-s duration and only 5-s period of the light off occurred.
Data were categorized as escape responses, omissions, premature responses, response
latency average, and total responses.
Rats were treated with either fluoxetine or vehicle for 21 days. Determination of
which rats received fluoxetine and which received vehicle were randomly assigned. Two
procedures took place – sucrose preference test and light aversion task (Figure 1).
Animals were tested and trained prior to fluoxetine administration and tested again after
21 days of administration. Following this, a washout period of two weeks given, and
testing was conducted 7 days (day 29) and 14 days (day 36) after the completion of
fluoxetine administration.
Experiment 1: Sucrose Preference Test.
During the execution of this test, animals were presented with two water bottles –
one with a 1% sucrose solution (Willner et al. 1987) and the other with tap water in
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standard housing cages. After 12 hours, the bottles were switched to avoid side
preference (Rygula et al. 2005).
Before fluoxetine administration.
For a period 72 hours before the sucrose preference test, the home cage water
bottles were filled with a 1% sucrose solution to acclimate rats to the sucrose water
(Bushnell et al., 1988; Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M.,
2012). On the day following this 72-hour period, two water bottles were wrapped in
aluminum foil and added to the home cages. One of the bottles contained a 1% sucrose
solution and the other contained tap water. Water bottles were weighed before and after
the 24-hour test session to determine sucrose and water consumption.
After fluoxetine administration.
On the final day of fluoxetine administration, fluoxetine was provided in two
water bottles placed in the home cage (or tap water for the fluoxetine control group). On
the next day, a sucrose preference test was conducted as described previously. After that,
both sucrose and fluoxetine were removed from home cages and testing was conducted
for light intensity motivation. Subsequent sucrose preference testing was conducted on
day 29 and day 36, after cessation of fluoxetine administration.
Experiment 2: Effects of light motivation on escape rates.
Test sessions that took place following fluoxetine treatment consisted of 20 trials,
and the session length was reduced, from 20 minute training session, to 10 minutes. Test
sessions were designed in accordance with how training sessions were administered.
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Data Analysis.
Sucrose consumption (based on water bottle weights), operant escape responses,
response omissions, premature responses, total responses, and response latencies served
as dependent variables in this study, and data were calculated as a percentage of baseline
and reported as means (+/- the standard error of the mean). Percent of baseline was
calculated by dividing the post-test value from the baseline value and multiplied by 100.
A fluoxetine group and a fluoxetine-vehicle group (non-treatment control) was assigned
for both male and female rats. Two-way, mixed factors analysis of variance (ANOVA)
tests were conducted within each sex across time and between treatment conditions for
each variable. Bonferroni post-hoc comparisons were used following statistically
significant ANOVA results. Unpaired t-tests were conducted to calculated differences in
body weight between treatment groups. Additionally, an unpaired t-test was calculated to
determine difference in fluoxetine consumption between female and male subjects.
Analyses carried out using GraphPad Prism version 8 for macOS (GraphPad, San Diego,
California.)
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Results

Fluoxetine Consumption
Figure 2, middle panel, represents the mean amount of fluoxetine consumption
over the course of the 21 day treatment. The mean fluoxetine consumption per day for
females (M = 19.94, SD = 1.770) was lower than mean fluoxetine consumption per day
for males (M = 24.97, SD = 2.023).
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Figure 2. Mean amount of fluoxetine water consumed by treatment group, water
containing 0.16g/L of fluoxetine
Body Weights
Mean weight for females is displayed in figure 3, left panel. Weight change in
females is displayed in figure 4, right panel. In females, there was a significant difference
found in weight change before and after treatment between the fluoxetine group (M =
10.44, SD = 10.24) and control group (M = -5.30, SD = 5.846); t(17) = 4.05, p < 0.001.
Females in the fluoxetine group gained weight throughout the experiment while females
in the vehicle group lost weight. Mean weights for males is displayed in figure 5, left
22

panel. Weight change in males is displayed in figure 6, right panel. There was no
significant difference found in males for weight change before and after treatment
between the fluoxetine group (M = -19.08, SD = 20.60) and the control group (M = 17.66, SD = 19.02); t (17) = 0.1560, p > 0.05. Signifying both groups of male subjects
lost weight throughout the experiment. This was due to male rats completely consuming
their daily allotted amount of food.
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Figure 3. Shows the pre vs. post treatment
mean weights for female subjects.

Figure 4. Shows the pre and post
mean weight change for female.
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Figure 5. Shows the pre vs. post treatment
mean weights for male subjects

Figure 6. Shows the pre and post
mean weight change for males.
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Sucrose Preference Test
The mean percentage of sucrose consumption during the sucrose preference test
for females is shown in figure 7, left panel. There was not a statistically significant
difference found between treatments (F [1, 17] = 0.322, p > 0.05). However, there was a
significant difference found across test days (F [3, 51] = 27.87, p < 0.0001). An increase
of sucrose consumption was found for fluoxetine treated females at day 22, day 29, and
day 36, when compared to baseline consumption. Similarly, females in the control group
showed an increase in sucrose consumption on day 22 and day 36 when compared to
baseline, but not day 29. The mean percentage of sucrose consumption for sucrose
preference test in males is shown in figure 8, right panel. A statistically significant
difference was not found between treatments (F [1, 17] = 5.381, p > 0.05). Similarly to
females, there was a significant difference found across test days for males (F [3, 51] =
13.03, p < 0.0001). There was an increase of sucrose consumption for fluoxetine treated
males at day 22, day 29, and day 36, compared to baseline. Additionally, male rats
receiving vehicle showed an increase in sucrose consumption at 22, when compared to
baseline.
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Figure 7. Shows the mean percentage of
sucrose consumption for females on each
test day.
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Figure 8. Shows the mean percentage of
sucrose consumption for males on each
test day.
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Light Aversion Operant Task
For the light aversion operant task, all females that completed training
(n=19), met the criteria after 20.89 (+/- SEM = 0.3749) sessions. One of the female rats
was removed from the study after repeatedly failing to emit responses in the chamber (the
rat instead spent the sessions chewing on the response aperture). All males (n = 19) met
the training criteria after mean of 19.26 (+/- SEM = 0.3749) daily training sessions. The
difference in sessions to training criteria between the male and female rats was
statistically different, t (7) = 4.337, p < 0.001.
The mean percentage of baseline for escape responses for females in the light
aversion task is shown in figure 9, left panel. A statistically significant difference was
neither found across test days (F [3, 48) = 1.300, p = 0.2852) nor between treatments (F
[1,16] = 0.001, p = 0.9713). There were no interaction effects present in female escape
behavior when comparing day 0 and day 22 (F [3,48] = 0.5512, p = 0.8487). Male mean
percentage of baseline for escape responses for in the light aversion task is shown in
figure 10, right panel. A statistically significant difference was neither found across test
days (F [3, 51] =1.218, p = 0.3126) nor between treatments (F [1, 17] = 0.365, p =
0.5538). However, there was a statistically significant interaction effect in males, (F [3,
51] = 3.061, p = 0.0359). A significant decrease in escape responses was found at day 22
for the fluoxetine treated male rats.

25

Escapes - Female

% of Baseline

100

Fluoxetine

80

Vehicle

60
40
20
0
0

22

29

36

Day of fluoxetine treatment

Figure 9. Shows the percentage of baseline Figure 10. Shows the percentage of baseline
as a mean of escape responses in females. as a mean of escape responses in males.
The mean percentage of baseline for omission responses for females in the light
aversion task is shown in figure 11, left panel. A statistically significant difference was
neither found across test days (F [3, 38] = 2.487, p = 0.0717) nor between treatments (F
[1, 16] = 0.455, p = 0.5094). There were no interaction effects found in female omission
responses (F [3,48] = 0.3012, p = 0.8244). Figure 12, right panel, displays the mean
percentage of baseline for omissions responses for males in the light aversion task. There
was not a statistically significant difference found across test days (F [3, 51] = 0.524, p =
0.1038) nor between treatments (F [3,17] = 0.148, p = 0.7054). There were no interaction
effects found in male omission responses (F [3,51] = 0.5239, p = 0.6678).
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in males.
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The mean percentage of baseline for premature responses for females in the light
aversion task is displayed in figure 13, left panel. A statistically significant difference
was neither found across test days (F [3, 48] = 1.954, p = 0.5501) nor between treatments
(F [1,16] = 0.880, p = 0.3620). Females did not display any interaction effects for
premature responses (F [3,48] = 1.954, p = 0.1335). The mean percentage of baseline for
premature responses for males in the light aversion task is shown in figure 14, right
panel. Again, there was not a statistically significant difference found across test days (F
[3, 51] = 1.077, p = 0.3673) or between treatments (F [1, 17] = 1.285, p = 0.2727). There
were no interaction effects found for male premature responses (F [3,51] = 1.236, p =
0.3061).
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Figure 14. Shows the percentage of
baseline as means of premature
responses in males.

Figure 15, left panel, represents the mean percentage of baseline for latency
average for females in the light aversion task. There was not a statistically significant
difference found across test days (F [3, 48] = 0.661, p = 0.5796) nor between treatments
(F [1, 16] = 0.002, p = 0.9624). There were no interaction effects found for female
latency averages (F [3,48] = 0.5297, p = 0.6641). The mean percentage of baseline for
latency average for males in the light aversion task is shown in figure 16, right panel.
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However, a statistically significant difference was neither found across test days (F [3,
51] =1.417, p = 0.2484) nor between treatments (F [1, 17] = 2.153, p = 0.1605). Males
did not display any interaction effects for latency average, either (F [3,51] = 0.4863, p =
0.6933).
The non-normative data for female latency averages is represented in figure 17,
left panel. Females did not display a significant difference across test days (F [3,48] =
0.4428 p = 0.7234) nor between treatments (F [1,16] = 1.513, p = 0.2365). There were no
significant interaction effects found for non-normative latency averages, either (F [3,48]
= 0.9503, p = 0.4238). The non-normative data for male latency averages is displayed in
figure 18, right panel. There were no significant differences found for males across test
days (F [3,51] = 1.717, p = 0.1752) nor between treatment groups (F [1,17] = 0.5415, p =
0.4718). Additionally, there were no significant interaction effects present for male nonnormative latency averages (F [3,51] = 0.2768, p = 0.8419).
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Figure 15. Shows the percentage of
baseline as means of latency average
in females.

Figure 16. Shows the percentage of
baseline as means of latency average
in males.
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Figure 17. Shows the non-normative
means of latency average in females.

Figure 18. Shows the non-normative
means of latency average in males.

The mean percentage of baseline for total responses for the females in the light
aversion task is shown in figure 19, left panel. There was not a statistically significant
difference found across test days (F [3, 48] = 1.042, p = 0.3826) nor between treatments
(F [1, 16] = 0.130, p = 0.7231). Females did not display any interaction effects for total
responses (F [3,48] = 0.6591, p = 0.5814). Figure 20, right panel, represents the mean
percentage of baseline for total responses for the males in the light avoidance task. Again,
a statistically significant difference was neither found across test days (F [3, 51] = 0.954,
p = 0.4214) nor between treatments (F [1, 17] = 1.417, p = 0.2503). Similarly, there were
no interaction effects present for male total responses (F [3,51] = 1.043, p = 0.3814).
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Discussion

The measures utilized in this study have shown reliability in examining
rewarding and aversive behavior in rats. Implementing a sucrose preference test was to
determine if fluoxetine had an effect on whether or not animals would still engage in a
rewarding stimulus (Li et al., 2012). The present study determined that fluoxetine
administration does not have an effect on sucrose consumption in rats, however this is
inconclusive. A different variation of acclimation may display other findings. The light
aversion operant task was used in the present research, as bright light has been
determined to be an aversive measure in albino rats (Barker et al., 2010). The present
study displayed significance in only one operant measure, escape responses. Males
treated with fluoxetine emitted significantly less amounts of escape behaviors when
compared to their male control group. Both female and male sex were used in the present
study to represent the human population that is likely to be given SSRI treatment.
Body Weights
As previously stated, SSRI treatment typically causes weight fluctuation with the
onset of treatment (Demyttenaere & Jaspers 2008). In this present study, significant
weight changes were found in the female fluoxetine group, when compared to those
receiving vehicle treatment. This is consistent with findings in human clinical studies
(Uher et al., 2011). However, in regards to the male sample in this present study, there
was a significant change in pre/post weights. These weight changes were observed for
both fluoxetine treated males and vehicle treated males. The change in weight for males
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can be attributed to their overconsumption of food before fluoxetine administration.
While males were not put on food-deprivation, they were consuming all of their food by
the next morning of feeding was given. Some male rats were reaching 600g before
fluoxetine treatment began, which is considered overweight for Wistar rats.
Sucrose Preference Test
The inclusion of the sucrose preference test was to determine if rats would engage
in a rewarding stimulus after chronic fluoxetine administration. While it was
hypothesized that rats who were treated with fluoxetine would have lower sucrose
consumption than that of the control group, the results indicated that there was no
significant difference. This was true for sex of the rats as well; neither male or female had
a significant change in sucrose consumption. A possible explanation for not seeing any
significant effect in the sucrose preference test could be due to fluoxetine not affecting
motivation for this type of reinforcer. Future studies might consider using additional
SSRI’s when using this test along with incorporating other types of reinforcers.
The results of this study are inconsistent with other findings on fluoxetine
treatment utilizing a sucrose preference test. Brenes & Fornaguera (2009) conducted an
experiment with the effects of social isolation and sucrose preference. Sucrose
consumption initially increased with social isolation. However, when a group was treated
with fluoxetine their sucrose consumption reduced significantly. This group of
researchers did use a different concentration of sucrose water (32%), and accumulated
data over a 48-hour time period, in contrast to the present study utilizing a 72-hour
acclimation period and a 24-hour test period (Brenes & Fornaguera, 2009).
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One reason that we failed to see a difference in sucrose consumption could be due
to the timeline of the sucrose preference test in relation to the beginning of fluoxetine
treatment. While other studies have shown that a 72-hour acclimation period was
sufficient (Li et al., 2012), it is possible that the 72-hour sucrose acclimation period was
too close to the sucrose preference test and subsequently the onset of fluoxetine
administration. However, Li et al. (2012), followed a differing protocol for a saccharin
preference test. Animals in the present study were given 72-hours of acclimation, while
Li et al (2012) gradually increase saccharin concentration from day 1 (0.025%) to day 2
(0.1%) and were then water-deprived for day 3 of acclimation. Present studies involving
sucrose preference would benefit from having a water-deprived 24-hours directly prior to
the 24-hour test session.
Light Aversion Operant Task
The purpose of this study was to determine if rats who are treated with fluoxetine
would respond differently to stimuli than rats who were not treated
pharmacologically. The hypothesis proposed that rats treated with fluoxetine would
engage less in the light aversion task when compared to the control group. A lessened
engagement in escaping an the aversive light, can be translated to a human who doesn’t
care to escape situations where they may be affected negatively. There was no significant
difference when sex was ignored in any of the operant tasks performed. However, there
was a significant difference between male rats treated with fluoxetine and male control
rats in one of the operant measures. Male rats treated with fluoxetine for 21 days
exhibited significantly lower amounts of escape behavior when compared to the control
group. This is supportive of the hypothesis that fluoxetine treatment lessens the
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engagement in escaping a negative stimulus, which is representative as a blunted affect
in rodents. Bright lights are shown to be an aversive stimulus in rodents (Barker et al.,
2010). Barker and colleagues expanded on this by determining rats would also avoid
bright light, by burrowing before the light was triggered, which should be a next step in
studying affective blunting as well. The results of prior studies have shown that
behavioral tasks in rodents have been reliable in translating to human behavior (Neumann
et al., 2011).
An increased number of omission responses would be an illustration of affective
blunting in rats, as greater omission responses would translate to not caring to terminate
the bright light. The present study hypothesized that omission responses would increase
after 21 days of fluoxetine administration, which we failed to see. While the graph does
appear to show an increase at day 22 when compared to day 0, its significance did not
meet cut-off criteria for females (p = 0.0717) or males (p = 0.1038).
Future Directions
Twenty days of training might not have been sufficient in establishing clear
learning behavior of the light aversion operant task. However, Barker et al (2010) were
able to establish significance in only 10 sessions of escape behavior. On average, each rat
participated in 20 training days. Training was established if the escape responding
behavior did not vary beyond the standard deviation of the last 5 days of training. Pre-test
data indicates that females performed escape behavior at 60.57% (fluoxetine group) and
60.22% (control group) of their baseline measures and males performed escape behavior
57-64% of their baseline measures. Subsequently, the omission responses were accounted
for in 48.91% (fluoxetine group) and 57.44% (control group) of the time in females,
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while males performed at 49.20% (fluoxetine group) and 45.75% (control group) of
baseline omission responses during pre-test. It is possible that using a longer time frame
of training would show increased escape response reliability. Another variable to
consider would be frequency of training.
Future studies in this area may consider adding various light intensities to their
testing paradigm, which was also suggested by Barker et al (2010). The benefit of
different light intensities added to the light aversion operant task may display a change in
responding when a weak aversive stimuli is presented versus a strong aversive stimuli. In
turn, this may correlate to the amount of aversive stimuli a human may be more apt avoid
while experiencing affective blunting.
Expanding this research onto other affective measures such as social isolation
would prove beneficial in the area of affective blunting. Case studies that were previously
mentioned report that individuals display an indifferent affect in emotional engagement
with family and/or peers (Price et al., 2009; Hoen-Saric et al., 1999). Brenes and
colleagues (2008) who conducted a study with chronic fluoxetine administration did so
while rodents were being reared. Further research with fluoxetine on adult rodents and
their social isolation may prove to be beneficial when moving forward with animal
models of affective blunting.
The benefit of utilizing additional species of animals in antidepressant drug
treatment is due to the fact that different species can offer unique perspectives into
behavioral representation. For example, different mice strains can respond differently to
one experiment such as effects of inescapable foot shock (Yan et al., 2010). Additionally,
the forced swim test paradigm is displayed differently in rodents and mice as well. The
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forced swim test can be effective in using mice within one exposure to their water, while
rats demonstrate the need to learn the task prior to testing (Yan et al., 2010). A next step
to be taken after rodent research, for affective blunting, would be the development of
nonhuman primate models. The benefit of utilizing nonhuman primates is due to their
increased similarity to human functioning (Phillips et al., 2014). Nonhuman primates
demonstrate complex behavior in environmental and social which are similar to humans.
Pharmacological treatment studies on primates can also mirror case studies that are often
difficult to do on human participants (Phillips et al., 2014).
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Conclusion

While significance was only seen in escape behavior for male rats treated with
fluoxetine, longer periods of training may result in significance found in the other operant
measures (i.e., omission response, premature response, total response, and latency
average). As previously mentioned, female percentage of baseline for omissions were
nearing significance following fluoxetine treatment (p = 0.0717) and changes to their
training criteria may display a significant increase in blunted affect in the form of an
omission response. Female rats may benefit from a longer training period due to their
estrous cycles, to display clear learning behavior. Females could also benefit from
additional testing days during their estrous cycle to see if it indeed has an effect on their
ability to respond. Another way to control for the female rat estrous cycle would be
utilizing ovariectomized rats, this would eliminate the need for monitoring which phase
of the cycle they were experiencing. The purpose of including females in this study is to
represent the large amount of female human population that is likely to be put on SSRI
treatment following diagnosis of a mood disorder such as Major Depressive Disorder,
and few studies typically utilize females. Future research in this area should look to
include females in their studies, as well.
Further research should look to include other SSRIs, a wider range of treatment
doses, and additional time courses of SSRI treatment. Applying this area of research to
other species (e.g., mice) would prove to be beneficial, as well. The assessment measures
of this research could also be expanded on. Implementing affective measures such as
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social interaction, mild stress, and/or ultrasonic vocalizations should be the next direction
taken in the research of affective blunting. This study is the first known attempt to model
affective blunting induced by chronic SSRI use in animals. The results from this research
give indication of which areas should be expanded on as future research progresses in this
side effect which may hinder quality of life in individuals on SSRI treatment.
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APPENDIX A
Non-normative Means for Sucrose and Water Consumption
Sucrose Total - Males

Sucrose Total - Females
150

Fluoxetine - Male

Fluoxetine - Female

ml of sucrose

ml of sucrose

200
150

Vehicle - Female
100
50

Vehicle - Male
100

50

0

0
0

22

29

0

36

29

36

H20 Total - Males

H20 Total - Females
80

60

Fluoxetine - Male

Fluoxetine - Female

ml of water

Vehicle - Female
ml of water

22

Day of sucrose preference test

Day of sucrose preference test

40

20

Vehicle - Male

60
40
20
0

0
0

22

29

0

36

22

29

36

Day of sucrose preference test

Day of sucrose preference test

Non-normative Means for Light Aversion Operant Task Values
Escapes - Male - Non-normative
Fluoxetine
Vehicle

15
10
5
0
0

22

29

36

Number of Escape Responses

Number of Escape Responses

Escapes - Female - Non-normative
20

20

Fluoxetine
Vehicle

15
10
5
0
0

Omissions - Female - Non-normative
15

Vehicle
10

5

0
22

29

29

36

Omissions - Male - Non-normative
Fluoxetine

0

22

Day of light aversion test

36

Number of Omission Reponses

Number of Omission Responses

Day of light aversion test

Day of light aversion test

20

Fluoxetine
Vehicle

15
10
5
0
0

22

29

Day of light aversion test

46

36

Fluoxetine
Vehicle

30
20
10
0
0

22

29

36

Number of Premature Responses

Number of Premature Responses

Premature - Female - Non-normative
40

Premature - Male - Non-normative
15

Fluoxetine
Vehicle

10

5

0
0

22

29

36

Day of light aversion test

Day of light aversion test

Non-normative Latency Averages - Female

Non-normative Latency Averages - Male

30

40

Fluoxetine

Fluoxetine
Vehicle

30

20

Time (s)

Time (s)

Vehicle

10

20
10

0

0
0

22

29

36

0

Day of light aversion test

Fluoxetine
Vehicle

40

20

0
22

29

29

36

Total Resp - Male - Non-normative
Number of Total Responses

Number of Total Responses

Total Resp - Female - Non-normative
60

0

22

Day of light aversion test

25

Fluoxetine

20

Vehicle

15
10
5
0

36

0

Day of light aversion test

22

29

36

Day of light aversion test

Non-normative Escape Responses
Day 0

Fluoxetine Female
Vehicle Female
Fluoxetine Male
Vehicle Male

Day 22

8.11
8.89
9.56
7.90

Day 29

5.89
7.78
6.56
8.30

6.67
7.56
6.67
7.40

Day 36

7.89
9.22
7.00
7.60

Non-normative Omission Responses
Day 0

Fluoxetine Female
Vehicle Female
Fluoxetine Male
Vehicle Male

Day 22

8.44
8.00
7.22
9.20

11.00
9.33
10.22
8.90
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Day 29

10.33
9.67
10.44
11.30

Day 36

8.67
8.22
9.44
9.20

Non-normative Premature Responses
Day 0

Fluoxetine Female
Vehicle Female
Fluoxetine Male
Vehicle Male

Day 22

3.33
7.44
6.00
4.10

Day 29

2.56
9.67
3.56
4.40

4.67
10.78
3.67
3.50

Day 36

4.67
11.89
3.89
4.30

Non-normative Latency Averages
Day 0

Fluoxetine Female
Vehicle Female
Fluoxetine Male
Vehicle Male

Day 22

22.12
21.00
21.27
20.50

Day 29

23.17
22.15
23.88
21.33

23.70
18.73
23.66
22.42

Day 36

22.22
20.66
23.89
21.86

Non-normative Total Responses
Day 0

Fluoxetine Female
Vehicle Female
Fluoxetine Male
Vehicle Male

Day 22

11.44
16.44
15.56
12.00

8.56
16.89
10.33
12.80
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Day 29

11.33
18.33
10.67
11.00

Day 36

12.33
21.11
11.11
12.00

APPENDIX B

Institutional Animal Care and Use Committee Approval Form

The approval from the Institutional Animal Care and Use Committee for use of
animal subjects in the present study has been copied and attached.
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